Pasithea Therapeutics (KTTA) Research & Development (2022 - 2026)
Pasithea Therapeutics (KTTA) posted Research & Development of $2.9 million for Q1 2026, down 62.93% sequentially from $7.9 million in Q4 2025, and up 70.09% YoY from $1.7 million in Q1 2025.
Pasithea Therapeutics (KTTA) Research & Development (2022 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Research & Development for 5 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Research & Development rose 70.09% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (down 4.56% YoY) and the FY2025 annual result came in at $8.0 million, up 10.87% from the prior year.
- Research & Development retreated to $2.9 million in Q1 2026 per KTTA's latest filing, from $7.9 million in the prior quarter.
- Over five years, Research & Development peaked at $7.9 million in Q4 2025 and troughed at $43000.0 in Q2 2025.
- A 5-year average of $2.5 million and a median of $1.7 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development jumped 141.73% in 2023, then tumbled 98.18% in 2025.
- Over 5 years, Research & Development stood at $1.4 million in 2022, then surged by 141.73% to $3.4 million in 2023, then soared by 114.78% to $7.2 million in 2024, then grew by 10.27% to $7.9 million in 2025, then tumbled by 62.93% to $2.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $2.9 million, $7.9 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Pasithea Therapeutics | 15.13 Mn | 15.13 Mn | - | 3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.94 Mn |
| Dec 31, 2025 | 7.94 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 7.20 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 2.36 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 1.39 Mn |
| Sep 30, 2022 | 1.16 Mn |